SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
06. September 2024 07:55 ET
|
SciSparc Ltd
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
11. Juni 2024 07:44 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
13. März 2024 08:14 ET
|
Clearmind Medicine Inc.
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery...
MAPS Announces Celestial Plans for Its 38th Anniversary
07. März 2024 12:34 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which celebrates its 38th anniversary on April 8, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival in Texas
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
01. Februar 2024 07:00 ET
|
Societal CDMO, Inc.
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing...
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
16. Januar 2024 16:27 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
05. Januar 2024 08:01 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
13. Dezember 2023 18:16 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
49ers’ Jon Feliciano supports MAPS as part of the 2023 NFL “My Cleats, My Cause” campaign
04. Dezember 2023 12:10 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS was featured on custom-designed cleats worn by Offensive Lineman Jon Feliciano during the San Francisco 49ers vs Philadelphia Eagles game
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
28. November 2023 08:25 ET
|
SciSparc Ltd
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- ...